Health Care & Life Sciences » Biotechnology | RegeneRX Biopharmaceuticals Inc.

RegeneRX Biopharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
29.50
-
60.60
93.30
56.70
69.70
Cost of Goods Sold (COGS) incl. D&A
-
4.80
-
-
-
-
Gross Income
-
4.80
-
-
-
-
SG&A Expense
938.70
1,550.70
1,766.70
1,550.00
1,284.20
1,390.30
EBIT
914.30
1,555.50
1,709.50
1,460.00
1,230.60
1,323.40
Unusual Expense
343.80
1,014.80
3,388.20
1,862.50
1,786.60
582.90
Interest Expense
100.90
183.50
172.90
173.40
170.90
87.30
Pretax Income
671.30
2,753.60
5,270.50
229.10
385.10
1,993.60
Income Tax
-
-
-
-
98.60
-
Consolidated Net Income
671.30
2,753.60
5,270.50
229.10
286.50
1,993.60
Net Income
671.30
2,753.60
5,270.50
229.10
286.50
1,993.60
Net Income After Extraordinaries
671.30
2,753.60
5,270.50
229.10
286.50
1,993.60
Net Income Available to Common
671.30
2,753.60
5,270.50
229.10
286.50
1,993.60
EPS (Basic)
0.01
0.03
0.05
0.00
0.00
0.02
Basic Shares Outstanding
81,733.20
93,186.40
112,191.60
106,787.20
107,442.90
120,716.30
EPS (Diluted)
0.01
0.03
0.05
0.00
0.00
0.02
Diluted Shares Outstanding
81,733.20
93,186.40
112,191.60
125,922.50
120,928.80
120,716.30
EBITDA
909.30
1,550.70
1,706.10
1,456.70
1,227.60
1,320.60
Non-Operating Interest Income
0.00
0.20
0.10
-
-
-

About RegeneRX Biopharmaceuticals

View Profile
Address
15245 Shady Grove Road
Rockville Maryland 20850
United States
Employees -
Website http://www.regenerx.com
Updated 07/08/2019
RegeneRx Biopharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, or Tß4, for tissue and organ protection, repair, and regeneration. The firm evaluates the commercial development of peptide fragments and derivatives of Tß4 for potential cosmeceutical and other personal care uses. Its products include RGN-259, RGN-352, and RGN-137.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.